Navigation Links
OPKO Completes Acquisition Of PROLOR Biotech
Date:8/29/2013

d on August 28, 2013. 

Barrington Research Associates, Inc., acted as the financial advisor to OPKO in connection with the transaction.  Jefferies LLC acted as financial advisor to PROLOR in connection with the transaction, and Oppenheimer & Co. provided a fairness opinion to PROLOR's Strategic Alternatives Committee.  Akerman Senterfitt acted as U.S. legal advisor to OPKO and Pearl Cohen Zedek Latzer Baratz acted as OPKO's legal advisor in Israel.  DLA Piper LLP (US) acted as legal advisor to PROLOR's Strategic Alternatives Committee, Greenberg Traurig, P.A. acted as U.S. legal advisor to PROLOR and Gornitzky & Co. acted as PROLOR's legal advisor in Israel.

ABOUT OPKO HEALTH, INC.
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit http://www.opko.com.

ABOUT PROLOR BIOTECH, INC.
PROLOR is a clinical stage biopharmaceutical company applying unique technologies, including patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  In addition to its long-acting version of human growth hormone, which successfully completed a Phase II clinical trial, PROLOR is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity.  For more information, visit http://www.prolor-biotech.com.SAFE HARBOR STATEMENT 
This press release contains "forward-l
'/>"/>

SOURCE OPKO Health, Inc.; PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sleep Nation, Inc. Completes 43 Acquisitions
2. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
3. InspireMD Completes First Phase of Manufacturing Upgrade and Partners with HealthLink for Global Logistics and Distribution Services
4. Immune Pharmaceuticals Completes Merger with EpiCept Corporation
5. MicuRx Completes $25 Million Series B Financing
6. Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.
7. ULURU Inc. Completes Redemption Of Preferred Stock
8. HedgePath Pharmaceuticals, Inc. Completes Reorganization Plan with Commonwealth Biotechnologies
9. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
10. Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
11. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
(Date:7/24/2014)... N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... manufacturing company, announced its financial results for the second quarter ... , Total revenues of $6.5 million in the ... same quarter in 2013 , Total revenues of $13.3 ... increase of 78% over the same period in 2013 ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... New results from the largest multicenter clinical trial for ... the International Society for Heart & Lung Transplantation (ISHLT) ...  Results show clinical benefit for the use of Everolimus ... 721 randomized patients at 67 medical centers spanning 5 ...
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
Cached Medicine Technology:Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 2Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 3Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 4Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2
(Date:7/25/2014)... The new report “Carbohydrase Market by Applications (Food ... Type (Amylases, Cellulases, and Others), Source (Microorganisms, Animals, ... Forecasts to 2019", by MarketsandMarkets, identifies the driving ... with analysis of trends, opportunities, winning imperatives, and ... forecasted on the basis of major regions such ...
(Date:7/25/2014)... 25, 2014 In today’s technological era, ... and supporting devices. This benefits the organization in various ... cyber attacks which can destroy the confidential information and ... Risk and Compliance (EGRC) manage and protect the enterprise ... can cause loss in dollars to the comp may. ...
(Date:7/25/2014)... NY (PRWEB) July 25, 2014 ... injury law firm with over 25 years of ... stemming from dangerous prescription drugs, announces the launch ... offer information to those who believe they have ... , The site offers valuable information about the ...
(Date:7/25/2014)... The European liquid chromatography reagents report defines ... and forecast of revenue. The liquid chromatography reagents market ... 2013, and is estimated to grow to around $1581.8 ... from 2013 to 2018. , Browse through the TOC ... an idea of the in-depth analysis provided. This also ...
(Date:7/25/2014)... the vast majority of adults finish all of the food ... new study. This is true for adults from ... Cornell University revealed. They noted their findings could help ... make better choices. "If you put it on your ... director of the Cornell Food and Brand Lab, said in ...
Breaking Medicine News(10 mins):Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 2Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 3Health News:Carbohydrase Market worth $3,717.7 Million by 2019 - Report by MarketsandMarkets 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:North America Enterprise Governance, Risk, and Compliance Market is Expected to Reach $3,972.6 Million in 2018 - New Report by MicroMarket Monitor 6Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Most Adults Are Members of 'Clean Plate Club' 2
... , , Psychiatric Care ... , , OAKLAND, Calif., July 27 ... a complaint against Mohamed El-Sabaawi with the California Medical Board ... a number of state mental health hospitals without a valid ...
... intensive therapy, study shows , MONDAY, July 27 (HealthDay ... taking medications that lower blood pressure and cholesterol, people ... of developing the most serious complications associated with the ... in the July 27 issue of the Archives ...
... , , , NEW ... medical technology company developing a minimally invasive drug delivery platform for the regional ... progress. In addition, the Company reported its financial results for the second ... , , , Screened 40 ...
... , ARLINGTON, Va., July 27 ... to the article in Pediatrics: H. von Rettberg, T. Hannman, U. ... Di(2-Ethylhexyl)Phthalate-Containing Infusion Systems Increases the Risk for Cholestasis, Pediatrics 124(2): 710-716 (August ... - delivery of nutrition intravenously via plastic tubing - is a life-saving ...
... , , , ... cover issues related to the diagnosis and treatment of infertility with ... including the emotional, scientific and financial aspects. Discussions include information about ... use of donor sperm or donor eggs. , , ...
... , , LOS ... Center specializes in cardiothoracic surgery including mitral valve replacement. Fatigue ... In fact, most people brush off these seemingly minor symptoms and ... of the need for mitral valve replacement ...
Cached Medicine News:Health News:Union of American Physicians and Dentists: Court Appointee El-Sabaawi Practicing Medicine Without a License? 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 2Health News:Tight Management of Type 1 Diabetes Worth the Effort 3Health News:Delcath Systems Provides Update on Progress 2Health News:Delcath Systems Provides Update on Progress 3Health News:Delcath Systems Provides Update on Progress 4Health News:Delcath Systems Provides Update on Progress 5Health News:Delcath Systems Provides Update on Progress 6Health News:Delcath Systems Provides Update on Progress 7Health News:ACC Responds to Study Published in Pediatrics About Phthalate and IV Tubing 2Health News:Southern California Surgical Center (heart411.com) Specializes in Mitral Valve Replacement 2